Gabapentin was originally marketed under the brand name Neurontin and since it became generic, it has been marketed under many other brand names. An extended-release formulation of gabapentin for once-daily administration was introduced in 2011 for postherpetic neuralgia under the brand name Gralise.
In the last several years, global market of Gabapentin developed rapidly, with an average revenue growth rate of 2.3%. In 2017, global revenue of Gabapentin is nearly 1431 M USD; the actual sales are about 8600 M Unit.
The global average price of Gabapentin is in the decreasing trend, from 218 USD/K Unit in 2013 to 167 USD/K Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Gabapentin includes Capsule and Tablet, and the proportion of Capsule in 2017 is about 55.2%.
Gabapentin is used primarily to treat seizures and neuropathic pain. It is also commonly prescribed for many off-label uses, such as treatment of anxiety disorders, insomnia, and bipolar disorder. There are, however, concerns regarding the quality of the trials conducted and evidence for some such uses, especially in the case of its use as a mood stabilizer in bipolar disorder.
The most proportion of Gabapentin is epilepsy, and the proportion in 2017 is about 54.1%.
North America is the largest consumption place, with a consumption market share nearly 33.2% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 30.5%. China is also an important sales region for the Gabapentin, In China, the price is lower than the developed countries.
Market competition is not intense. Pfizer, Depomed, TEVA, Mylan, Arbor Pharma, etc. are the leaders of the industry, with high-end customers.